Bristol Myers Squibb names new executive vice president

PRINCETON, N.J. - Bristol Myers Squibb (NYSE: BMY), a prominent player in the pharmaceuticals industry with a market capitalization of $102 billion and annual revenue exceeding $47 billion, has announced the appointment of Cari Gallman as the new Executive Vice President, General Counsel, and Chief Policy Officer. According to InvestingPro data, the company maintains a "GOOD" financial health rating, positioning it well for future growth. Gallman steps into the role with immediate effect, following the retirement of Sandra Leung, who served the company for 33 years.

Gallman, who has been with Bristol Myers Squibb for a decade, will oversee the law department, managing areas such as intellectual property, litigation, and compliance, as well as global policy. Her most recent position within the company was as Executive Vice President, Corporate Affairs. The company has demonstrated strong financial stability, maintaining dividend payments for 55 consecutive years while achieving a healthy gross profit margin of 75%.

Christopher Boerner, board chair and CEO of Bristol Myers Squibb, praised Gallman’s diverse expertise in legal, policy, and communications, as well as her leadership skills. He expressed confidence in her ability to guide the company’s legal and policy teams in their ongoing endeavors to deliver innovative treatments to patients with serious diseases.

Gallman herself commented on the honor of leading the teams at Bristol Myers Squibb and her commitment to upholding the company’s integrity and patient-focused policies.

The company also acknowledged the contributions of Sandy Leung, the retiring executive, highlighting her resilience and dedication to patient advocacy, as well as her significant impact on the organization. For investors seeking deeper insights into Bristol Myers Squibb’s performance and prospects, InvestingPro offers comprehensive analysis with 10+ additional exclusive ProTips and detailed financial metrics in its Pro Research Report, one of 1,400+ available for top US stocks.

Gallman’s background includes roles such as Chief Compliance and Ethics Officer at Bristol Myers Squibb, where she promoted the company’s culture of integrity. She began her career in private practice, representing pharmaceutical and medical device manufacturers in various complex legal matters. Gallman is a Princeton University alumna and holds a JD from Harvard Law School.

This leadership change is based on a press release statement from Bristol Myers Squibb, a company devoted to developing medicines for the treatment of serious diseases. The information reflects the company’s ongoing commitment to leadership in the pharmaceutical industry.

In other recent news, Bristol-Myers Squibb Company reported impressive financial results for the first quarter of 2025, exceeding expectations with earnings per share of $1.80, compared to the anticipated $1.52. The company’s revenue also surpassed forecasts, reaching $11.2 billion against the expected $10.68 billion. Despite these positive results, BofA Securities maintained a Neutral rating on Bristol-Myers Squibb, although it increased the price target to $56 from $54. Analysts at BofA noted the company’s valuation aligns with peers and highlighted potential earnings challenges due to generic competition pressures.

Additionally, Bristol-Myers Squibb raised its full-year revenue guidance to a range of $45.8 billion to $46.8 billion, reflecting confidence in its growth portfolio and strategic initiatives. The company aims for $2 billion in annual cost savings by 2027, focusing on strategic productivity. New product launches, including COBENFY for schizophrenia, contributed to the company’s strong performance, underscoring its competitive position in the pharmaceutical industry. Investors and analysts will likely continue to monitor Bristol-Myers Squibb’s ability to navigate these challenges while maintaining growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.